GlassScriptPhysician profile
Sonia Bahroo
NPI 1053367441
$7,372.87
in general payments reported to CMS, 2019-2025
29 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $2,324 · 2023: $1,657 · 2024: $1,315 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $1,394.04 | 2021-2024 | Afrezza |
| Lilly USA, LLC | $860.01 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $656.10 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Cequr Corporation | $622.57 | 2022-2025 | Cequr Simplicity |
| Corcept Therapeutics | $505.68 | 2021-2025 | Korlym |
| Insulet Corporation | $427.42 | 2022-2023 | Omnipod |
| Beta Bionics, INC. | $375.08 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $356.84 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $304.29 | 2021-2025 | |
| Amgen INC. | $274.28 | 2021-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $261.32 | 2023-2025 | Freestyle Libre 3, Freestyle Libre, Proclaim |
| Astrazeneca Pharmaceuticals LP | $238.54 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.36 | 2021-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $135.64 | 2022-2023 | Unithroid |
| Sanofi-Aventis U.S. LLC | $92.23 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $86.70 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $83.24 | 2021-2025 | |
| Zealand Pharma US, INC. | $77.44 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.83 | 2022-2025 | |
| Sequel Med Tech, LLC | $56.44 | 2025 | Twiist |
| Embecta Corp. | $52.33 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Recordati_rare_diseases_inc. | $46.45 | 2025 | Isturisa |
| Boston Scientific Corporation | $34.45 | 2025 | Solyx Sis System |
| Cumberland Pharmaceuticals, INC. | $27.02 | 2021 | |
| Lifescan, INC. | $25.27 | 2023 | |
| Merck Sharp & Dohme LLC | $22.42 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.02 | 2024 | Strensiq |
| Acerus Pharmaceuticals Corporation | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Bahroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.